ETHNOPHARMACOLOGICAL RELEVANCE:Rheumatoid arthritis (RA) is a severe systemic autoimmune disease characterized by progressive joint destruction. Spatholobi Caulis (SC), derived from the vine stem of Spatholobus suberectus Dunn, has a long history of clinical application in traditional Chinese medicine for activating blood circulation and relieving rheumatic arthralgia. However, its pharmacological material basis and anti-angiogenic mechanisms for treating RA remain insufficiently elucidated.
AIM OF THE STUDY:To systematically investigate the active constituents of SC and elucidate its anti-angiogenic mechanisms in RA using an integrated approach combining chemical profiling, network pharmacology, and in vivo experimental validation.
MATERIALS AND METHODS:The chemical profile of SC was characterized using HPLC-QE-MS. A network pharmacology approach-incorporating target screening, protein-protein interaction (PPI) analysis, and GO/KEGG enrichment-was utilized to predict core targets and pathways. Molecular docking, molecular dynamics (MD) simulations and Surface plasmon resonance (SPR) were performed to evaluate the binding stability between key active compounds and hub targets. Finally, the anti-arthritic and anti-angiogenic effects were validated in a collagen-induced arthritis (CIA) rat model using micro-CT, H&E, immunohistochemistry (CD31), ELISA, and Western blot analysis. Additionally, to directly verify the predicted interactions, the effects of the core compound 7,3',4'-trihydroxyisoflavone (THIF) on TNF-α-induced MH7A cells were assessed. Cell proliferation, VEGF secretion, migration, and protein expression of EGFR and PIK3CB were evaluated after 24 h treatment with THIF.
RESULTS:HPLC-QE-MS identified 24 active ingredients in SC. Network analysis identified key hub targets including SRC, PIK3CB, AKT1, EGFR, and ESR1 and revealed that SC predominantly modulates the PI3K/AKT, HIF-1α, and VEGF signaling pathways. Molecular docking, MD simulations and SPR demonstrated strong binding affinities and high structural stability between core compounds (e.g., THIF, Hesperetin, Afzelechin, (-)-Maackiain) and key hub targets (e.g., PIK3CB, EGFR, ESR1). In vivo, SC administration significantly alleviated joint swelling, preserved bone morphology (increased BV/TV and BMD via micro-CT), and reduced the organ indices of the thymus and spleen. Crucially, SC remarkably suppressed synovial neovascularization (decreased CD31-positive vessels), downregulated systemic inflammatory and angiogenic cytokines (IL-1β, TNF-α, IL-6, VEGF, TGF-α), and significantly inhibited the protein expression of SRC, STAT3, EGFR, PI3K, AKT, and HIF-1α in synovial tissues. In vitro experiments demonstrated that SC effectively inhibits the proliferation of MH7A cells. Flow cytometry analysis confirmed that SC significantly induces apoptosis in MH7A cells; However, this pro-apoptotic effect was alleviated upon addition of the PI3K inhibitor LY294002. Further in vitro validation with the pure compound THIF showed that it dose-dependently suppressed TNF-α-induced MH7A cell proliferation, reduced VEGF secretion from 292.18 to 80.32 pg/mL, and inhibited cell migration. Western blot analysis confirmed that THIF significantly downregulated the protein expression of EGFR and PIK3CB in a dose-dependent manner, directly validating the SPR binding results and demonstrating targeted inhibition of the downstream pathological signaling pathways associated with RA.
CONCLUSION:SC effectively ameliorates RA progression by mitigating synovial inflammation and preventing structural joint damage. Its therapeutic efficacy is primarily driven by the suppression of pathological angiogenesis via the targeted dual-inhibition of the EGFR/PI3K/AKT/HIF-1α signaling axes.